GLP-1 Market
LLY $1351.20 ▼ -2.3% NVO $38.89 ▼ -1.4% PFE $27.57 ▼ -1.7% VKTX $25.84 ▼ -1.3% KLRA $11.58 ▼ -1.8% GPCR $17.12 ▼ -1.4% RHHBY $59.01 ▼ -0.8%
Market data delayed up to 20 min · Source: Twelve Data
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Garetosmab

Company
Regeneron Pharmaceuticals
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 19, 2026

Find a Clinical Trial Near Me

See recruiting studies for Garetosmab and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT02745158

    The Fibrodysplasia Ossificans Progressiva (FOP) Registry

    The International FOP Association 800 participants Est. completion 2040-12-31 1 site
    Other conditions: Fibrodysplasia Ossificans Progressiva (FOP)
    View official trial listing →
  • Recruiting NCT NCT04479072

    Aspirin and Preeclampsia

    Not yet reported University of Chicago 180 participants Est. completion 2026-12-31 1 site
    Other conditions: Preeclampsia Postpartum
    View official trial listing →
  • Completed NCT NCT01589016

    Activin A and Inhibin A in Predicting Outcome of Pregnancies of Unknown Location After Assisted Reproductive Technology

    Instituto Valenciano de Infertilidad, IVI VALENCIA 96 participants Est. completion 2012-07 1 site
    Other conditions: Ectopic Pregnancies
    View official trial listing →
  • Completed NCT NCT01604642

    Role of Activin A (ActA) in the Human Cancer Cachexia

    Not yet reported Cliniques universitaires Saint-Luc- Université Catholique de Louvain 150 participants Est. completion 2016-01-01 1 site
    Other conditions: Colorectal Cancer, Lung Cancer
    View official trial listing →
  • Completed NCT NCT02019095

    Clinical and Biological Markers in Acute Respiratory Failure

    University of Athens 55 participants Est. completion 2014-12 2 sites
    Other conditions: Ventilator-Associated Pneumonia, Acute Respiratory Distress Syndrome
    View official trial listing →
  • Withdrawn NCT NCT02328742

    Development of a Bioabsorbable Medical Device for the Prevention of Postoperative Intra-uterine Adhesions.

    Centre Hospitalier Universitaire de Nīmes Est. completion 2018-05 3 sites
    Other conditions: Infertility, Abortion, Spontaneous, Embryo Implantation, Delayed
    View official trial listing →
  • Completed NCT NCT02870400

    A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477

    Not yet reported Regeneron Pharmaceuticals 41 participants Est. completion 2017-01-12 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT02943239

    Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men

    Not yet reported Regeneron Pharmaceuticals 82 participants Est. completion 2019-04-30 2 sites Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT03162042

    Role of Myostatin, Activin A and Follistatin Cachexia of ENT Cancers

    University Hospital, Clermont-Ferrand 60 participants Est. completion 2017-05 1 site
    Other conditions: Cachexia, Squamous Cell Carcinoma, Head and Neck Cancer
    View official trial listing →
  • Completed NCT NCT03188666

    A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

    Not yet reported Regeneron Pharmaceuticals 44 participants Est. completion 2021-09-16 11 sites Stand-alone
    Other conditions: Fibrodysplasia Ossificans Progressiva
    View official trial listing →
  • Withdrawn NCT NCT03710941

    Safety and Efficacy of REGN2477+REGN1033 in Patients With Sporadic Inclusion Body Myositis

    Not yet reported Regeneron Pharmaceuticals Est. completion 2020-11-05 Stand-alone
    Other conditions: Sporadic Inclusion Body Myositis
    View official trial listing →
  • Status unknown NCT NCT04489251

    Assessment of the TGF-beta Pathway and Micro-RNA in Pediatric Pulmonary Arterial Hypertension

    Medical College of Wisconsin 40 participants Est. completion 2023-01-01 1 site
    Other conditions: Pulmonary Arterial Hypertension
    View official trial listing →
  • Completed NCT NCT04525404

    MOIST Study: Multi-Organ Imaging With Serial Testing in COVID-19 Infected Patients

    University of Alberta 215 participants Est. completion 2022-09-30 2 sites
    Other conditions: Covid19, Coronavirus Infection, SARS-CoV Infection
    View official trial listing →
  • Withdrawn NCT NCT04577820

    Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)

    Not yet reported Regeneron Pharmaceuticals Est. completion 2022-10-08 Stand-alone
    Other conditions: Fibrodyplasia Ossificans Progressiva (FOP), Heterotopic Ossification (HO)
    View official trial listing →
  • Active, not recruiting NCT NCT05394116

    A Study to Assess Safety, Tolerability and Efficacy of Garetosmab Versus Placebo Administered Intravenously (IV) in Adult Participants With Fibrodysplasia Ossificans Progressiva (FOP)

    Not yet reported Regeneron Pharmaceuticals 63 participants Est. completion 2029-02-27 22 sites Stand-alone
    Other conditions: Fibrodysplasia Ossificans Progressiva
    View official trial listing →
  • Active, not recruiting NCT NCT05534932

    Guideline-directed Management and Therapy (GDMT) for the Prevention of Postpartum Cardiac Dysfunction in Preeclamptic African American Women

    Not yet reported University of Chicago 20 participants Est. completion 2026-11-01 1 site
    Other conditions: Preeclampsia Postpartum
    View official trial listing →
  • Status unknown NCT NCT05794737

    Immunohistochemical Expression of Inhibin Beta A (INHBA) in Colorectal Carcinoma

    Sohag University 60 participants Est. completion 2024-06-30 1 site
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Completed NCT NCT06064656

    A Non-Interventional Study of Clinical Characteristics and Mortality of US Patients With Fibrodysplasia Ossificans Progressiva (FOP)

    Regeneron Pharmaceuticals 131 participants Est. completion 2023-09-29 1 site
    Other conditions: Fibrodysplasia Ossificans Progressiva (FOP)
    View official trial listing →
  • Completed NCT NCT06110221

    Activin-A and Interleukin-1β Levels in Periodontitis

    Aydin Adnan Menderes University 75 participants Est. completion 2020-02-02 1 site
    Other conditions: Periodontitis, Gingivitis, Periodontal Health
    View official trial listing →
  • Not yet recruiting NCT NCT06188533

    Urinary Activin A as Apredictive Marker for Assessement of Acute Kidney Injury Severity in Patient Admitted at Assuit University Hospital

    Assiut University 70 participants Est. completion 2026-12-05
    Other conditions: Urinary Activin A in AKI
    View official trial listing →
  • Completed NCT NCT06299098

    A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation

    Not yet reported Regeneron Pharmaceuticals 1005 participants Est. completion 2026-10-21 60 sites Added to GLP-1
    Other conditions: Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT06508021

    A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

    Not yet reported, Not yet reported Ashibio Inc 92 participants Est. completion 2029-02-04 3 sites
    Other conditions: Fibrodysplasia Ossificans Progressiva
    View official trial listing →
  • Withdrawn NCT NCT06970405

    Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women

    Not yet reported Regeneron Pharmaceuticals Est. completion 2026-06-08 Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Active, not recruiting NCT NCT07253363

    Circulating Activin-A and FSTL3 in Precapillary Pulmonary Hypertension

    Not yet reported Assistance Publique - Hôpitaux de Paris 550 participants Est. completion 2028-04 1 site
    Other conditions: Pulmonary Hypertension
    View official trial listing →
  • Approved For Marketing NCT NCT07301450

    An Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)

    Regeneron Pharmaceuticals
    Other conditions: Fibrodysplasia Ossificans Progressiva (FOP)
    View official trial listing →
  • Not yet recruiting NCT NCT07559513

    A Study to Investigate the Safety, Pharmacokinetics (PK), and Efficacy of Garetosmab in Children and Adolescents With Fibrodysplasia Ossificans Progressiva (FOP)

    Not yet reported Regeneron Pharmaceuticals 18 participants Est. completion 2030-07-08 Stand-alone
    Other conditions: Fibrodysplasia Ossificans Progressiva, FOP
    View official trial listing →
  • Completed NCT NCT07637435

    Role of Vascular Endothelial Markers in Predicting Renal Prognosis and Mortality in Patients Undergoing HD-AKI

    Not yet reported Muğla Sıtkı Koçman University 170 participants Est. completion 2025-12-15 1 site
    Other conditions: Acute Kidney Injury, Hemodialysis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Garetosmab, Pasatru, REGN2477, Activin A

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.